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FLOW-THROUGH FILTER TO REMOVE
ALUMINUM FROM MEDICAL SOLUTIONS

TABLE !-continued
Alwninwn content of the most contaminated SVP solutions
Solution Aluminum concentration (micrograrns/L)

This utility patent application claims the benefit of priority
in U.S. Provisional Patent Application Ser. No. 61/768,006
filed on Feb. 22, 2013 and is a continuation-in-part of U.S.
patent application Ser. No. 13/278,498, filed on Oct. 21, 2011,
now U.S. Pat. No. 9,139,456, which is a continuation-in-part
of U.S. patent application Ser. No. 13/052,477, filed on Mar.
21, 2011 which is now issued U.S. Pat. No. 8,066,883 and is
a divisional of U.S. patent application Ser. No. 12/104,066,
filed on Apr. 16, 2008 which is now issued U.S. Pat. No.
7,932,326, the entirety of the disclosures of which are incorporated herein by reference.

Potassium Acetate
Sodium acetate

1
From Poole et al., Pediatr. Gastroenterol. Nutr. 2010, 50: 208; Poole et al., J. Pediatr.
Pharmacal. Ther. 2011, 16: 92.
2From Beaney and Smeaton, Congress of the EuropeanAssociation ofHospital Pharmacists,
2010.
3
10 From de Oliveira et al., JPEN JParenterEnteral Nutr 2010,34:322-328.
4FromAdvenier et al., J. Pediatr. Gastroenterol. Nutr. 2003,36: 448.

15

TECHNICAL FIELD
This document relates generally to filter assemblies for
removing metal ions from a solution and, more particularly, to
a filter assembly capable of removing trivalent ions, such as
aluminum, and tetravalent metal ions, from medical solutions.
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BACKGROUND
Aluminum (AI) is a common contaminant in many medical
solutions. This is in part the result of the widespread distribution of aluminum in the environment. In addition, some
medical solutions contain compounds that react strongly with
aluminum and extract this metal from the surroundings, e.g.
from the walls of glass containers. This strong binding
increases the AI contamination and makes it much more difficult to remove the aluminum from these solutions.
Healthy adults are generally protected against oral aluminum toxicity by the fact that less than 1% of an oral dose of
aluminum is absorbed from the intestine. In addition, the
urinary excretion of aluminum is relatively effective for persons with normal kidney function.
There is a special concern regarding aluminum exposure to
premature neonates. These infants routinely require several or
more days of parenteral nutrition (PN) until they can tolerate
oral feeding. The PN bypasses the normal protection associated with low intestinal absorption of AI. In addition, these
infants often have underdeveloped kidney function (the primary route ofAI elimination), which impedes the excretion of
the aluminum contained in the PN solution.
It is well known that some of the small volume parenteral
(SVP) solutions used to prepare the final PN solutions are
heavily contaminated with aluminum. Poole, co-workers and
others have extensively documented the AI content of SVP
solutions, as shown in Table 1.

30

35

40

45

50

55

TABLE 1
Aluminwn content of the most contaminated SVP solutions
Solution Aluminum concentration (micrograrns/L)
Calcium gluconate
and 19,4003
Potassium phosphate
Sodium Phosphate
Multi-trace elements
Potassiwn Lactate

3234 and 1920 to 34951,4900 (new) and
6145 (old glass arnpoules) 2 , 9205
8280 and 3650 to 16,820 1
622 and 17 to 3281 1
414 and 101 to 739\ 1049 and 2065 3
1500 4

42 and 11 to 1120 1
83 and 54 to 138 1

60

65

Because of the relative volumes of each of these solutions
included in a typical PN preparation, most of the final AI
content originates from the calcium gluconate SVP solution.
It is noteworthy that the AI content of calcium gluconate can
vary widely, depending on the commercial provider.
Reported AI concentrations range from 1920 to 19,400 micrograms/L. At a typical concentration of 4,000 micrograms/L, it
is estimated that calcium gluconate contributes about 80% of
the aluminum in the final PN solution (Mouser eta!., Am. J.
Health-Syst. Pharm., 1998, 55: 1071).
The FDA has formally recognized the problem of potential
AI toxicity to premature infants. It has established a safe level
of AI exposure as 4 to 5 micrograms/kg/d. However, it is
widely recognized that currently the U.S. pharmaceutical
industry cannot supply SVP component solutions that allow
pediatric pharmacists to prepare PN solutions that meet this
exposure limit.
Other patient populations at risk include, but are not limited to, children with malabsorption syndrome, dialysis
patients, elderly patients (due to a weakened GI protective
barrier and/or normal renal function deterioration) and burn
patients (due to Al-contaminated albumin to maintain oncotic
pressure). In addition, critically ill infants and children
require parenteral calcium replacement because of hypocalcemia, especially after cardiac surgery. More specifically, the
amount of calcium required, provided as calcium gluconate,
would lead to exposure to much greater than 5 micrograms of
aluminum per kg per day. Removal of aluminum from these
parenteral infusions would minimize potential aluminuminduced toxicities.
Disclosed herein is a single-use filter to remove aluminum
from a solution as it passes through the filter. The body of the
filter is filled with a specialized chelator, such as trihydroxamate chelating resin, described in our previous U.S. Pat.
Nos. 7,932,326 and 8,066,883 and U.S. patent application
Ser. No. 13/278,498 the full disclosures of which are incorporated herein by reference. The other components of the
filter are designed to produce a controlled fluid flow rate,
using a partially evacuated vial and a flow restriction/flow
controller tube that has an internal diameter and length, that
when paired with the extent of vacuum in the partially evacuated vial, achieves a desired flow rate. The filter is designed to
connect to the evacuated vial and the vial of the source SVP
solution.
Chelating resins are not new. Chelex 100® is a polystyrene
resin which has iminodiacetic acid functional groups
covalently linked to the resin. It is relatively non-selective,
and thus is widely used to bind a large number of metal ions.
However, we have determined that this type of generic chelating resin is not effective for removing aluminum from solutions such as calcium gluconate.
The concept of a flow-through filter for removing contaminants from aqueous solutions is also widely used. There are
many examples of point-of-use filters for home faucets to
remove both metal ions and organic contaminants. These
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typically remove metal ions by simple cation exchange. Thus
they are not designed to compete against strong Al-binding
ligands in the solution. More specialized chelating resins
have been used in filters in research labs, but they have not
been applied to the removal of aluminum from SVP solutions.
Flow-through filters have been used in medical settings.
The chelating agent desferrioxamine has been physically
imbedded into a hollow-fiber filter for the extracorporeal
removal of iron and aluminum from blood during hemodialysis. Desferrioxamine has also been covalently bound to silica
for the extracorporeal removal of metal ions from blood.
Neither of these filters has been suggested for use in a pharmaceutical setting for removing aluminum from SVP solutions.

still other different embodiments and their several details are
capable of modification and various obvious aspects. Accordingly, the drawings and descriptions will be regarded as illustrative in nature and not as restrictive.
BRIEF DESCRIPTION OF THE DRAWINGS
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SUMMARY
In accordance with the purposes noted above, a flow
through filter assembly is provided for removing trivalent and
tetravalent metal ions from a solution. In one embodiment,
the flow through assembly includes a housing containing a
hydroxamate chelating resin. The housing has an inlet and an
outlet. A first vial connector is provided in fluid communication with the inlet. A second vial connector is provided in fluid
communication with the outlet. Further the filter assembly
includes a flow controller for limiting flow through the housing to a predetermined rate. In one useful embodiment that
predetermined rate is less than 2.0 ml/min. In another useful
embodiment the predetermined rate is less than 1.0 ml/min. In
yet another useful embodiment that predetermined rate is
about 1.0 ml/min.
In one useful embodiment the first container connector is a
vented spike and a first set of connector clips. In another
useful embodiment the second container connector is a nonvented spike and a second set of connector clips. The second
vial has a negative interior pressure before the non-vented
spike is inserted into the second vial.
In accordance with an additional aspect a system is provided for removing a trivalent or tetravalent metal ion from a
solution. The system comprises a first vial including a solution from which the trivalent or tetravalent metal ion is to be
removed and a second vial for receiving a treated solution.
The second vial has a negative interior pressure. Further the
system includes a filter assembly for capturing the trivalent or
tetravalent metal ion. The filter assembly is connected
between the first and second vials.
The filter assembly includes a first connector for the first
vial and a second connector for the second vial. The first
connector is a vented spike and a first clamp. The second
connector is a non-vented spike and a second clamp.
In accordance with yet another aspect, a flow-through filter
assembly for removing metal ions from a medical solution,
including aluminum ions, comprised of a housing including a
medical solution inlet, an aluminum metal ion capturing
agent having anAl-binding constant of at least approximately
1020 held in the vessel and a treated medical solution outlet.
The treated medical solution outlet is positioned relative to
the medical solution inlet to allow flow of medical solution
through the filter assembly without a mechanical pump. Further, the assembly includes a flow controller for maintaining
a rate of flow of medical solution through the filter assembly
that allows capture of aluminum metal ions by the capturing
agent.
In the following description there are shown and described
a number of different embodiments of a flow-through filter
assembly and an associated system. It should be realized that
the flow-through filter assembly and system are capable of

20

The accompanying drawings incorporated herein and
forming a part of the specification, illustrate several aspects of
the filter assembly and system and together with the description serve to explain certain principles thereof. In the drawings:
FIG.1 is an exploded perspective view of the flow-through
filter assembly.
FIG. 2 is a perspective view of the system for removing a
trivalent or tetravalent metal ion from a solution.
FIG. 3 is a detailed cross-sectional view illustrating the
filter assembly.
FIG. 4 is a graph of flow rate versus restrictor tube length
for a flow restrictor tube of0.005" (0.127 mm) diameter at a
draw pressure of 88,046.11 pascal (26 inHg)
Reference will now be made in detail to the present preferred embodiments of the flow-through filter assembly and
system illustrated in the accompanying drawings.
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Reference is now made to FIG. 1 generally illustrating the
flow-through filter assembly 10 for removing trivalent and
tetravalent metal ions from a solution. The flow-through
assembly 10 includes a housing 12 containing a chelating
agent or resin having an Al-binding constant of at least
approximately 10 20 . In one useful embodiment that chelating
agent is a trihydroxamate chelating resin. It should be appreciated, however, that other chelating agents/resins may be
used including, but not limited to, desferrioxamine chelating
resin, tetrahydroxamate chelating resin, hydroxypyridinone
chelating resin, aminocarboxylate chelating resin, catechol
chelating resin, poly-carboxylate chelating resin and mixtures thereof.
As further illustrated in FIG. 1, the flow-through filter
assembly 10 includes a first container connector 14 at a first
end and a second container connector 16 at a second end. In
one possible embodiment the first container connector 14 is
comprised of a vented spike 15 (note vent 18) and a first set of
connector clips or clamp 38. In one possible embodiment the
second container connector 16 comprises a non-vented spike
17 and a second set of connector clips or clamp 40.
The housing 12 contains the upper resin frit 24. The upper
membrane housing 20 holds the lower resin frit 26. The resin
is held between frits 24 and 26 during use of the filter assembly 10 (see also FIG. 3).
The filter assembly 10 also includes a lower membrane
housing 28 including a grating 30 that supports a 0.2 or 0.45
micron filter membrane 32. That membrane 32 functions to
make certain that no particulates from the chelating agent or
resin in the housing 12 are carried into the treated solution that
is collected in the second container 104 (FIG. 2). Such a filter
membrane 32 may be built-in as an integral component of the
filter assembly 10. Alternatively, a 0.2 or 0.45 micron filter
cartridge may be inserted between the housing 12 and the
lower, non-vented spike 17.
As further illustrated in FIGS. 1 and 3, a flow controller 34
is provided within the control tube aperture 36 of the nonvented spike 17. This flow controller 34 functions to limit the
flow of solution through the filter assembly 10 to a rate of
between 0.1 and 10 ml/min. In another embodiment the flow
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controller 34limits the rate of flow to less than 2.0 ml/min. In
another embodiment the flow controller 34 limits the rate of
flow to less than 1.0 ml/min. In yet another, the flow controller
34limits the rate of flow to about 1.0 ml/min. In the illustrated
embodiment, the flow controller 34 is a flow restrictor tube
with an internal flow passage 35. It should be appreciated that
the flow controller 34 does not have to be a tube, it can be
molded directly into the spike 17, or a hole could be drilled in
the spike to create a tube (passage) for fluid flow. The selected
flow rate insures that there is sufficient time for trivalent and
tetravalent metal ions in the solution to be captured by the
chelating agent in the housing 12 as the solution flows
through the housing 12.
As previously noted, it should be appreciated that the first
container connector 14 includes the first set of clips 38 and the
second container connector 16 includes the second set of clips
40. More specifically, the first set of clips 38 is engineered to
snuggly clip onto the caps of a commercial container of SVP
solution while the second set of clips 40 is engineered to
snuggly clip onto an appropriately sized evacuated container
so that the working system 100 (see FIG. 2) can be assembled
conveniently and quickly and with no other clamping devices.
More specifically, with reference to FIG. 2, the system 100
includes: (a) a first vial or container 102 including a solution
from which the trivalent or tetravalent ion is to be removed;
(b) a second vial or container 104 for receiving a treated
solution; and (c) the filter assembly 10 for capturing the
trivalent or tetravalent metal ion. More specifically, as shown
in FIG. 1 the clips 38 at the first end of the filter assembly 10
engage a cap 106 (FIG. 2) of the firstcontainer102 effectively
holding the vented spike 15, that is inserted into the vial
through a puncturable seal in the cap, in fluid communication
with the solution contained in the container. Similarly, the
second set of clips 40 at the second end of the filter assembly
10 engage the cap 108 of the second container 104 effectively
holding the non-vented spike 17, that is inserted into the vial
through a puncturable seal in the cap, in fluid communication
with the interior chamber of that container. The vent 18 to
ambient atmosphere provided on the vented spike 15 works in
conjunction with the negative pressure in the chamber of the
second container 104 to produce a steady flow of solution
from the first container 102 through the filter assembly 10
including the chelating agent or resin held in the housing 12
and the 0.2 or 0.45 micron membrane 3 2 to the chamber of the
container 104. It should be appreciated that the chelating
agent or resin in the housing 12 is specifically designed for
high aluminum binding affinity enabling efficient extraction
of aluminum even from solutions that contain high concentrations of competing aluminum complexing agents such as
gluconate or phosphate.
More specifically, in one possible embodiment the trihydroxamate resin has an aluminum-binding constant of
approximately 1020 . This binding is strong enough to compete with the aluminum-binding ligands present in contaminated SVP solutions. However, the rate at which the aluminum binds to the resin is a critical factor. This rate can be slow,
either because of the slow chemical exchange of aluminum
between the solution and the immobilized chelating agent or
because of the time required for the solution to pass through
the porous structure of the resin beads. Thus, a key element in
the design of the filter assembly is the ability to regulate the
rate of flow ofliquid through the filter assembly 10 to ensure
sufficient contact time with the resin to produce effective
aluminum removal. Toward this end, the filter assembly 10
includes the flow controller 34 built in the control tube aperture36 of the lower spike (see FIG. 3). The inner diameter and
length of the flow restriction/flow controller tube 34 is

selected to produce the appropriate flow rate for efficient
aluminum removal from the targeted medical solution, in
concert with the level of reduced pressure in the second container, and other components of the filter 10. More specifically, a larger inner diameter flow restriction/flow controller
tube 34 provides a faster flow rate. In contrast, a smaller inner
diameter flow restriction/flow controller tube 34 provides a
slower flow rate.
Still more specifically, the flow restrictor tube 34 of the
illustrated embodiment includes the flow passage 35 which
has a predetermined length L of between about 5 mm and
about 20 mm and a predetermined diameter ofbetween about
0.0508 mm and about 0.1778 mm. Further the second container 104 has a negative interior pressure P ofbetween about
84,659.72 pascal and about 94,818.88 pascal. The difference
in the ambient pressure provided in the first container 102 by
the vent 18 on the spike 15 and the negative pressure in the
second container 104 functions to pull the solution through
the filter assembly 10, including the flow passage 35. Thus, it
should be appreciated that the flow passage length L, the flow
passage diameter D and the second container interior pressure
P function together to provide the desired rate of flow of
solution through the filter assembly 10.
Accordingly, the filter assembly 10 is engineered to provide the proper flow rate for removing the desired trivalent
and/or tetravalent metal ions from the solution being treated.
The operator does not need to adjust any pumps or monitor
any equipment to provide the required flow rate. Thus, proper
filtering of trivalent and tetravalent metal ions from the solution is ensured with minimal potential for any error.
The following examples are presented to further illustrate
the flow-through filter 10 and system 100.
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We have prepared a filter assembly 10 specifically engineered for the removal of AI from calcium gluconate. The
upper connector 14 is engineered to fit the neck of standard
10, 50 and 100 ml vials 102 of calcium gluconate.
The trihydroxamate chelating resin was initially tested in
stirred, batch extractions to establish its ability to remove AI
from calcium gluconate. A 1 g sample of resin was added to
100 ml of commercial calcium gluconate solution that was
gently agitated by an overhead stirrer. In this configuration,
the resin removed 80% of the AI. Based on the Al-binding
constants of gluconate, the binding constant of the ligand
immobilized on the resin was calculated to be 1020 .4.
Approximately 1 g ofligand was loaded into a housing 12,
and a calcium gluconate solution was pulled through the filter
by an evacuated collection vial 104. The fraction of AI
removed at various flow rates was measured. Aluminum
removal is inversely related to flow rate. The flow can be
changed by changing the inner diameter and length of the
flow restriction/flow controller tube and the partial vacuum.
Different applications may require a different flow rate. Thus
the inner diameter of the flow restriction/flow controller tube
34 in the present embodiment has been adjusted to produce a
flow of calcium gluconate of -1 ml/min. For example, where
the lower spike 17 has a flow restriction/flow controller tube
34 with an inner flow diameter of about 0.004 inches and a
length of about 9;16 inches, the flow rate of calcium gluconate
through the filter is about 1 ml/min. Flow rate will be a
function of the inner diameter of the flow restriction/flow
controller tube 34, the length of the flow restriction/flow
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controller tube 34, the level of vacuum in the second container
3. The filter of claim 1 wherein said predetermined rate is
104, the viscosity of the fluid flowing through the filter assemless than 2.0 ml/min.
bly 10, and other properties of the filter. For example, for eight
4. The filter of claim 1, wherein said predetermined rate is
experiments, where the flow restriction/flow controller tube
less than 1.0 ml/min.
inner diameter was 0.004", its length 9 mm and the level of
5. The filter of claim 1, wherein said predetermined rate is
vacuum in the second container 104 was negative 27.1±0.1
about 1.0 ml/min.
inches of mercury in relation to atmospheric pressure, the
6. The filter of claim 1, wherein said first container conflow rate of calcium gluconate averaged 0.93 ml/min. For six
nector includes a vented spike and a first set of connector
experiments, where the flow restriction/flow controller tube
clips.
inner diameter was 0.004", its length 10 mm and the level of 10
7. The filter of claim 1, wherein said second container
vacuum in the second container 104 was negative 27 inches of
connector includes a non-vented spike and a second set of
mercury in relation to atmospheric pressure, the average flow
connector clips.
rate of calcium gluconate was 0.92 g/min. For twelve experi8. The filter of claim 1, wherein said second vial has a
ments, where the flow restriction/flow controller tube inner
diameter was 0.004", its length 12 mm and the level of 15 negative interior pressure.
9. The filter of claim 1, wherein said flow controller comvacuum in the second container 104 was negative 27.5 inches
prises a flow restrictor tube having a flow passage with a
of mercury, the average flow rate of calcium gluconate was
predetermined length L of between about 5 mm and about 20
1.25 g/min. When nine experiments were conducted for
mm and a predetermined inner diameter of between about
which the inner diameter of the flow restriction/flow controller tube inner diameter was 0.005", its length was varied, and 20 0.0508 mm and about 0.1778 mm.
10. A system for removing a trivalent or tetravalent metal
the level of vacuum in the second container 104 was 26 inches
ion from a solution, comprising:
of mercury, calcium gluconate flow rate inversely related to
a first container including a solution from which said trivathe length of the flow restriction/flow controller tube (FIG. 4).
These are examples of the method to control the flow rate
lent or tetravalent metal ion is to be removed;
using two dimensions of the flow restriction/flow controller 25
a second container for receiving a treated solution, said
tube 34 (internal diameter and length) with the level of
second vial having a negative interior pressure;
vacuum in the second container 104. Other dimensions of
a filter assembly for capturing and containing the trivalent
these three variables can be used to achieve the same flow
or tetravalent metal ion, said filter assembly being connected between said first container and said second conrate. Other properties of the filter, such as the membranes,
also influence the flow rate.
30
tainer.
The amount of resin loaded into the body of the cartridge
11. The system of claim 10, wherein said filter assembly
was also varied. In four replicate experiments, 1 g of resin
includes a first connector for said first container and a second
removed 91 to 95% of the aluminum from a commercial
connector for said second container.
12. The system of claim 11, wherein said first connector is
calcium gluconate solution that had an initial AI concentration of -4,000 micrograms/L. Further tests showed that 800 35 a vented spike and a first clamp.
mg of resin removed 79% of the AI, and 600 mg of resin
13. The system of claim 11, wherein said second connector
removed only 64% of theA!. The column/cartridge 12 of the
is a non-vented spike and a second clamp.
14. The system of claim 11, wherein said first connector is
present filter assembly 10 has been engineered to hold 1 g of
resm.
a vented spike and a first clamp and said second connector is
Since the AI concentration in commercial calcium glucon- 40 a non-vented spike and a second clamp.
15. The system of claim 10, wherein said filter assembly
ate solutions can vary, we also tested the present embodiment
of the filter assembly 10 with calcium gluconate solutions that
includes a flow controller comprising a flow restrictor tube
had been spiked with added AI to give total AI concentrations
having a flow passage with a predetermined length L of
of 8,000 and 11,200 micrograms/L. The filter assembly 10
between about 5 mm and about 20 mm, a predetermined inner
removed 94% and 90% of the aluminum, respectively, from 45 diameter D of between about 0.0508 mm and about 0.1778
mm and said second container has a negative interior pressure
these spiked solutions
of between about 84,659.72 pascals and about 94,818.88
The foregoing has been presented for purposes of illustration and description. It is not intended to be exhaustive or to
pascals, whereby said flow passage length L, said flow paslimit the embodiments to the precise form disclosed. Obvious
sage diameter D and said second container pressure P funcmodifications and variations are possible in light of the above 50 tion together to provide a rate of flow of solution through said
teachings. All such modifications and variations are within
filter assembly of between about 0.1 ml/min and about 10.0
the scope of the appended claims when interpreted in accorml/min.
16. A flow-through filter assembly for removing aluminum
dance with the breadth to which they are fairly, legally and
metal ions from a medical solution including said aluminum
equitably entitled.
What is claimed:
55 metal ions comprising:
1. A flow-through filter assembly for removing trivalent
a housing including a medical solution inlet;
an aluminum metal ion capturing agent having anAl-bindand tetravalent metal ions from a solution, comprising:
ing constant of at least -10 20 held in said housing;
a housing containing a trihydroxamate chelating resin, said
a treated medical solution outlet positioned on said housing
housing having an inlet and an outlet;
a first container connector in fluid communication with 60
relative to said medical solution inlet to allow for flow of
said inlet;
medical solution through said filter assembly without a
a second container connector in fluid communication with
mechanical pump; and
said outlet; and
a flow controller for maintaining a rate of flow of medical
solution through said filter assembly that allows capture
a flow controller for limiting flow through said housing to
65
of aluminum metal ions by said capturing agent.
a predetermined rate.
2. The filter of claim 1, wherein said predetermined rate is
17. The filter assembly of claim 16, wherein said rate of
flow is less than 2.0 ml/min.
between 0.1 and 10 ml/min.
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18. The filter assembly of claim 16, wherein said rate of
flow is between about 0.1 ml/min and about 10.0 ml/min.
19. The filter assembly of claim 16, wherein said resin is a
trihydroxamate chelating resin.
20. The filter assembly of claim 16, wherein said aluminum
metal ion capturing agent is selected from a group consisting
of trihydroxamate chelating resin, desferrioxamine chelating
resin, tetrahydroxamate chelating resin, hydroxypyridinone
chelating resin, aminocarboxylate chelating resin, tricatechol
chelating resin, poly-carboxylate chelating resin and mixtures thereof.
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